Peer Review Report

Review Report on Comparison of uremic toxin removal between expanded hemodialysis and high volume online hemodiafiltrations in different modes

Original Research, Acta Biochim. Pol.

Reviewer: Menso Nube Submitted on: 23 Sep 2024

Article DOI: 10.3389/abp.2024.13715

EVALUATION

Q 1 Please summarize the main findings of the study.

The main findings include the removal, as measured by RRs, of four uremic retention products (range from 500D-40kD) during four high-efficiency dialysis modalities.

From this study, it appeared that statistical significant differences could not be demonstrated during a single dialysis session.

Q 2 Please highlight the limitations and strengths.

The present study is well designed, executed and written. Important limitations are the lack of Ht-based hemoconcentration calculations and a control HF-HD arm.

Q 3 Please comment on the methods, results and data interpretation. If there are any objective errors, or if the conclusions are not supported, you should detail your concerns.

The authors should omit the term SIGNAL (page 7, 10) or 'best degree of clearance' (page 8), because there is no evidence at all -not even a trend-, that the removal of any uremic substance is superior in either modality

Check List

Q 4 Please provide your detailed review report to the editor and authors (including any comments on the Q4 Check List)

This study is important, because it may support the start of the missing link in this area, namely a RCT, comparing survival between HV-HDF and HDx. As HDx is as easy to perform as standard HD and, hence, available all over the world, comparable survival could benefit thousands of patients who are (either by location or by an inability to reach high convection volumes) restrained from HV-HDF.

Q 5 Is the English language of sufficient quality?

Yes.

Is the quality of the figures and tables satisfactory?

Yes.

Q 6

	boes the reference list cover the relevant i	iterature adequately and in an unbiased manner?
No.		
Q 8	Are the statistical methods valid and corre	ctly applied? (e.g. sample size, choice of test)
Yes.		
Q 9	Are the methods sufficiently documented t	to allow replication studies?
Yes.		
_	 Are the data underlying the study available itory? (Sequence/expression data, protein/m my data are required to be deposited in publi 	
No.	ny data are required to be deposited in publi	re repositories prior to publication,
Q 11 procedu		s including ethics committee approval and consen
		s including ethics committee approval and consen
procedi		s including ethics committee approval and consen
procedi		s including ethics committee approval and consen
procedi		
procedi Yes. Q 12	ure? Have standard biosecurity and institutiona	
procedi Yes. Q 12	ure? Have standard biosecurity and institutiona	
yes. Q 12 Not Appl	Have standard biosecurity and institutiona icable.	
Procedu Yes. Q 12 Not Appl	Have standard biosecurity and institutiona icable. ASSESSMENT	
Procedity Yes. Q 12 Not Appl QUALITY Q 13	Have standard biosecurity and institutiona icable. ASSESSMENT Originality	
Procedu Yes. Q 12 Not Appl	Have standard biosecurity and institutiona icable. ASSESSMENT	
Procedity Yes. Q 12 Not Appl QUALITY Q 13	Have standard biosecurity and institutiona icable. ASSESSMENT Originality	
Procedu Yes. Q 12 Not Appl Q 13 Q 14 Q 15	Have standard biosecurity and institutiona icable. ASSESSMENT Originality Rigor	
Procedu Yes. Q 12 Not Appl Q 13 Q 14	Have standard biosecurity and institutiona icable. ASSESSMENT Originality Rigor Significance to the field	
Procedu Yes. Q 12 Not Appl Q 13 Q 14 Q 15 Q 16	Have standard biosecurity and institutiona icable. ASSESSMENT Originality Rigor Significance to the field Interest to general audience	